Minerva Neurosciences (NASDAQ:NERV) Research Coverage Started at StockNews.com

StockNews.com assumed coverage on shares of Minerva Neurosciences (NASDAQ:NERVGet Rating) in a research report issued on Sunday. The firm set a “sell” rating on the biopharmaceutical company’s stock.

Several other analysts have also recently issued reports on NERV. HC Wainwright decreased their price objective on Minerva Neurosciences to $5.00 and set a “buy” rating on the stock in a report on Friday, March 4th. Zacks Investment Research raised Minerva Neurosciences from a “sell” rating to a “hold” rating in a research report on Saturday.

NASDAQ NERV opened at $0.43 on Friday. The stock has a market cap of $18.37 million, a PE ratio of -0.36 and a beta of 1.13. Minerva Neurosciences has a 12 month low of $0.33 and a 12 month high of $3.14. The stock’s 50 day moving average is $0.62 and its 200 day moving average is $0.77.

Minerva Neurosciences (NASDAQ:NERVGet Rating) last issued its quarterly earnings data on Wednesday, May 4th. The biopharmaceutical company reported ($0.23) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.18) by ($0.05). As a group, sell-side analysts predict that Minerva Neurosciences will post -0.82 earnings per share for the current fiscal year.

A number of institutional investors have recently made changes to their positions in the business. Acadian Asset Management LLC grew its position in Minerva Neurosciences by 3.4% in the 4th quarter. Acadian Asset Management LLC now owns 1,768,685 shares of the biopharmaceutical company’s stock valued at $1,414,000 after acquiring an additional 58,202 shares during the last quarter. Millennium Management LLC grew its position in shares of Minerva Neurosciences by 2.6% during the 4th quarter. Millennium Management LLC now owns 799,398 shares of the biopharmaceutical company’s stock worth $640,000 after buying an additional 19,977 shares in the last quarter. BlackRock Inc. grew its position in shares of Minerva Neurosciences by 3.7% during the 4th quarter. BlackRock Inc. now owns 506,457 shares of the biopharmaceutical company’s stock worth $406,000 after buying an additional 18,087 shares in the last quarter. Geode Capital Management LLC grew its position in shares of Minerva Neurosciences by 9.7% during the 3rd quarter. Geode Capital Management LLC now owns 488,813 shares of the biopharmaceutical company’s stock worth $850,000 after buying an additional 43,034 shares in the last quarter. Finally, GSA Capital Partners LLP grew its position in shares of Minerva Neurosciences by 26.0% during the 3rd quarter. GSA Capital Partners LLP now owns 480,629 shares of the biopharmaceutical company’s stock worth $836,000 after buying an additional 99,141 shares in the last quarter. 48.59% of the stock is currently owned by institutional investors.

About Minerva Neurosciences (Get Rating)

Minerva Neurosciences, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of product candidates for the treatment of central nervous system diseases. Its lead product candidate is roluperidone for the treatment of schizophrenia; and MIN-301, a soluble recombinant form of the neuregulin-1b1 protein for the treatment of Parkinson's disease and other neurodegenerative disorders.

Featured Articles

Receive News & Ratings for Minerva Neurosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Minerva Neurosciences and related companies with MarketBeat.com's FREE daily email newsletter.